Basel, Switzerland – October 30, 2025 — Roche Holding AG (SIX: RO, ROG; OTCQX: RHHBY) has successfully completed its tender offer and acquisition of 89bio, Inc. (NASDAQ: ETNB), a clinical-stage biopharmaceutical company specializing in metabolic and liver diseases. Roche’s wholly owned subsidiary, Bluefin Merger Subsidiary, Inc., accepted all validly tendered shares at $14.50 per share in cash, plus a non-tradeable contingent value right (CVR) for milestone payments up to $6.00 per share. Following this transaction, 89bio becomes a wholly owned Roche subsidiary, marking a significant strategic expansion in metabolic and cardiometabolic drug development.
Science Significance
The acquisition strengthens Roche’s innovation pipeline in metabolic dysfunction-associated steatohepatitis (MASH) and severe hypertriglyceridemia (SHTG)—diseases with limited therapeutic options. 89bio’s lead candidate, pegozafermin, is a fibroblast growth factor 21 (FGF21) analog designed using proprietary glycoPEGylated technology to extend half-life and optimize biological activity. Currently in Phase 3 trials, pegozafermin shows promise as a potential best-in-class therapy for advanced liver fibrosis. Roche’s integration of this platform enhances its scientific reach across metabolic pathways and precision hepatology, broadening the company’s translational research capabilities.
Regulatory Significance
The completion of Roche’s tender offer represents a fully compliant cross-border merger under U.S. and Swiss securities laws, following all Delaware merger regulations and U.S. SEC tender offer protocols. The transaction’s successful closure highlights Roche’s adherence to international cGxP, Good Laboratory, and Clinical Practice standards, reflecting its commitment to transparency, quality, and scientific integrity. This move also underscores regulatory confidence in 89bio’s clinical programs, especially pegozafermin’s progression into late-stage evaluation aligned with global standards for biotherapeutics.
Business Significance
Advertisement
From a business perspective, this $1.7 billion transaction marks Roche’s strategic re-entry into the cardiometabolic disease landscape, complementing its established oncology and diagnostics franchises. By securing 89bio’s advanced pipeline, Roche gains a strong foothold in the fast-growing non-alcoholic steatohepatitis (NASH/MASH) therapeutic market, projected to exceed $30 billion by 2030. The acquisition provides Roche with valuable clinical assets, IP rights, and proprietary FGF21 engineering expertise, enhancing its biopharma diversification strategy. This acquisition also reinforces Roche’s M&A momentum, signaling continued investment in precision medicine and biotherapeutics innovation.
Patients’ Significance
For patients, this merger promises accelerated development and potential access to transformative therapies targeting metabolic and liver disorders that currently have limited treatment options. Pegozafermin could address severe complications associated with MASH-related fibrosis, offering a targeted approach that modulates lipid metabolism, inflammation, and insulin sensitivity. Through Roche’s global manufacturing and regulatory infrastructure, patients worldwide may benefit from faster clinical development timelines, expanded access programs, and integrated companion diagnostic support.
Policy Significance
The acquisition aligns with global health priorities, including the World Health Organization’s non-communicable disease (NCD) roadmap, by addressing the growing burden of metabolic disorders. It demonstrates how strategic partnerships between pharma and biotech can accelerate the translation of advanced science into accessible treatments. Roche’s investment reinforces European and U.S. biopharma policy goals—particularly in fostering innovation ecosystems that combine public health impact, sustainability, and long-term disease prevention. The deal also supports Roche’s commitment to achieving net-zero carbon operations by 2045, integrating environmental responsibility into its acquisition strategy.
With the acquisition of 89bio, Roche cements its position as a global leader in biotechnology and diagnostics, expanding its scientific footprint into metabolic and hepatology innovation. The merger exemplifies how science-driven acquisitions can create synergies across discovery, development, and patient outcomes. As 89bio’s programs advance within Roche’s ecosystem, the partnership is expected to yield new therapeutic breakthroughs that align with Roche’s mission—“Doing now what patients need next.”
Source: Roche press release
